Migraine prevention is appropriate for patients with frequent (typically ≥4-6 attacks/month), severe, or refractory migraine. The pharmacologic options have expanded dramatically — from older agents (beta-blockers, anticonvulsants, antidepressants) to anti-CGRP monoclonal antibodies, gepants, and continued use of botulinum toxin for chronic migraine. Modern preventive choice depends on comorbidities, side effect profile, cost considerations, and patient preference. This page covers the preventive armamentarium.

Indications for Preventive Therapy

  • ≥4 migraine days/month with disability.
  • ≥8 migraine days/month even with mild attacks.
  • Significant disability from migraine.
  • Failure or contraindication to acute therapy.
  • Medication overuse headache.
  • Patient preference.

Classical Preventive Agents

Beta-Blockers

  • Propranolol: 60-240 mg/day; most evidence; first-line.
  • Timolol: 10-30 mg/day; FDA-approved.
  • Metoprolol: 100-200 mg/day.
  • Nadolol: 40-160 mg/day.
  • Mechanism likely cardiovascular + cortical modulation.
  • Adverse: fatigue, depression, bradycardia, bronchospasm, exercise intolerance.
  • Avoid in severe asthma, advanced AV block, decompensated heart failure.
  • Useful for: hypertension comorbidity, anxiety, essential tremor.

Antidepressants

  • Amitriptyline: 10-100 mg HS; first-line TCA; sleep + mood + migraine benefit.
  • Nortriptyline: alternative; less anticholinergic.
  • Venlafaxine: 75-225 mg/day SNRI; effective.
  • Duloxetine: less evidence.
  • Mechanism: serotonergic, noradrenergic, anticholinergic modulation.
  • Adverse: anticholinergic (TCAs), weight gain, sexual dysfunction.
  • Useful for: depression, anxiety, sleep, fibromyalgia comorbidities.

Anticonvulsants

  • Topiramate: 50-200 mg/day; most evidence; useful for: weight loss, epilepsy comorbidity.
    • Adverse: cognitive (“dopamax”), paresthesias, weight loss, renal stones, cleft palate.
    • Reduces OC efficacy at higher doses.
  • Valproate: 500-1500 mg/day; effective but limited by AVOID in women of childbearing age, weight gain, hair thinning, tremor, hepatotoxicity, pancreatitis.
  • Gabapentin, pregabalin: limited evidence for migraine prevention.

Calcium Channel Blockers

  • Verapamil: 240-480 mg/day; first-line for cluster headache prevention; modest migraine evidence.
  • Flunarizine: outside US; effective for migraine.
  • Cinnarizine: outside US.

Other Classical

  • Methysergide: 5-HT2 antagonist; historical; retroperitoneal fibrosis; rarely used.
  • Lisinopril, candesartan: ARB/ACE; modest evidence; useful for HTN comorbidity.
  • Magnesium: 400-600 mg/day; modest evidence; first-line in pregnancy alternative.
  • Riboflavin (B2): 400 mg/day; nutritional supplement; weak evidence.
  • Coenzyme Q10: 100-300 mg/day; weak evidence.
  • Feverfew: weak evidence.
  • Butterbur: hepatotoxicity concerns; no longer recommended.

Anti-CGRP Monoclonal Antibodies

Major advance in migraine prevention; monthly or quarterly SC/IV; well-tolerated:

Erenumab (Aimovig)

  • Anti-CGRP receptor monoclonal.
  • 70 mg SC monthly (or 140 mg if needed).
  • For episodic and chronic migraine.
  • Possible constipation (rare); injection site reactions.

Fremanezumab (Ajovy)

  • Anti-CGRP ligand monoclonal.
  • 225 mg SC monthly OR 675 mg SC quarterly.
  • For episodic and chronic migraine.

Galcanezumab (Emgality)

  • Anti-CGRP ligand monoclonal.
  • 240 mg loading, then 120 mg SC monthly.
  • For episodic and chronic migraine; ALSO FDA-approved for cluster headache prevention.

Eptinezumab (Vyepti)

  • Anti-CGRP ligand monoclonal.
  • 100-300 mg IV every 12 weeks.
  • For episodic and chronic migraine.
  • Rapid onset (within days for some patients).

Anti-CGRP Considerations

  • 50% responder rate ~50-60%; 30% responder rate higher.
  • Modest cost in past; insurance coverage improving.
  • Pregnancy: limited data; generally avoid.
  • Cardiovascular safety: emerging concerns about hypertension in some.
  • Constipation: variable across agents.

Gepants for Prevention

  • Rimegepant (Nurtec ODT): 75 mg every other day for prevention; ALSO acute treatment.
  • Atogepant (Qulipta): 10-60 mg daily for episodic and chronic migraine prevention.
  • Mechanism: oral CGRP receptor antagonism.
  • Convenience: oral, no injection.
  • Adverse: nausea, fatigue, constipation.
  • Increasingly used; emerging place in therapy.

Botulinum Toxin (OnabotulinumtoxinA)

  • Chronic migraine: ≥15 headache days/month, ≥8 with migraine features.
  • 155 units, 31 injection sites, 7 muscle groups (PREEMPT protocol).
  • Every 12 weeks.
  • Modest evidence in chronic migraine (50% responder rate ~50%).
  • NOT for episodic migraine.
  • Costly; insurance coverage requires documentation.

Cluster Headache Prevention

  • Verapamil: 240-960 mg/day; first-line; ECG monitoring at high doses.
  • Galcanezumab: FDA-approved for episodic cluster.
  • Corticosteroids: short-term bridge during cluster bout.
  • Topiramate: 50-200 mg/day; alternative.
  • Lithium: 600-1200 mg/day; chronic cluster.
  • Greater occipital nerve block: short-term bridge.
  • Sphenopalatine ganglion block: refractory.

Tension-Type Headache Prevention

  • Amitriptyline: first-line.
  • Mirtazapine, venlafaxine: alternatives.
  • Behavioral: relaxation, biofeedback, CBT.

Idiopathic Intracranial Hypertension (IIH) / Pseudotumor

  • Weight loss: most effective.
  • Acetazolamide: 1-4 g/day; first-line pharmacotherapy.
  • Topiramate: alternative (weight loss benefit).
  • Methazolamide.
  • Furosemide: adjunctive.
  • CSF shunt or optic nerve sheath fenestration for refractory.

Trigeminal Neuralgia

  • Carbamazepine: first-line; 100 mg BID start, titrate to 800-1200 mg/day.
  • Oxcarbazepine: alternative; often better tolerated.
  • Lamotrigine, baclofen: alternatives.
  • Gabapentin, pregabalin: alternatives.
  • Surgical options: microvascular decompression, gamma knife, percutaneous balloon compression.

Migraine in Pregnancy Prevention

  • Magnesium: first-line.
  • Beta-blockers (propranolol, metoprolol): often used.
  • Anti-CGRPs: limited data; usually avoided.
  • Anticonvulsants: many teratogenic.

Pediatric Migraine Prevention

  • CHAMP trial: amitriptyline and topiramate not superior to placebo in children.
  • Address triggers; behavioral interventions.
  • Try when severe and impairing.

Combination Therapy

  • Acceptable to combine agents with different mechanisms.
  • Beta-blocker + amitriptyline.
  • Anti-CGRP + classical (some studies showing additional benefit).
  • Botox + anti-CGRP: some specialists use; FDA approval evolving.

Duration of Therapy

  • Try preventive for 8-12 weeks before judging efficacy.
  • If successful: continue 6-12 months, then attempt taper.
  • If recurrence: reinstate.
  • Some patients require lifelong prevention.

🔍 Did You Know?

The development of anti-CGRP monoclonal antibodies and gepants represents the first migraine-specific preventive class — and it transformed an entire patient population’s outlook. For decades, migraine prevention relied on drugs originally developed for other conditions (beta-blockers for hypertension, antidepressants for depression, anticonvulsants for epilepsy) with significant tolerability issues. CGRP (calcitonin gene-related peptide) was identified as central to migraine pathophysiology through decades of basic and clinical research — released from trigeminal nerves during attacks, it drives vasodilation, neurogenic inflammation, and pain transmission. The discovery that blocking CGRP could prevent migraine led to development of: monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) for monthly or quarterly administration; oral gepants (rimegepant, atogepant, ubrogepant, zavegepant) for daily or as-needed use. The clinical impact: 50-60% of patients achieve ≥50% reduction in migraine days, often without significant side effects. For practicing neurologists, the lesson is profound: understanding molecular pathophysiology can produce targeted preventive therapy, and the CGRP class has become first-line for many patients with frequent migraine. The cost remains a concern, but the safety profile and efficacy have established this class as central to modern migraine care. Future developments include longer-acting agents and combination strategies (e.g., CGRP + botulinum toxin).

Pitfalls and Pearls

  • Indications: ≥4-8 migraine days/month with disability; preference; MOH.
  • Propranolol: first-line classical; consider for HTN comorbidity.
  • Amitriptyline: TCA; sleep + mood benefit; anticholinergic.
  • Topiramate: cognitive trade-off; weight loss; reduces OC efficacy.
  • Valproate: AVOID in women of childbearing age.
  • Venlafaxine: SNRI; effective for migraine; mood benefit.
  • Anti-CGRP mAbs: erenumab, fremanezumab, galcanezumab, eptinezumab; monthly/quarterly; well-tolerated.
  • Gepants for prevention: rimegepant (every other day), atogepant (daily); oral convenience.
  • Botox: chronic migraine only (≥15 days/month); 155u, 31 sites.
  • Cluster prevention: verapamil first-line; galcanezumab FDA-approved.
  • Trigeminal neuralgia: carbamazepine first-line.
  • IIH/Pseudotumor: weight loss + acetazolamide.
  • Try 8-12 weeks: before judging efficacy.
  • Try 2 doses minimum: anti-CGRPs may take 2-3 doses for full effect.
  • Pregnancy prevention: magnesium first-line; beta-blockers often used.
  • Combine: classical + anti-CGRP often beneficial.

References

  1. Silberstein SD. Preventive migraine treatment. Continuum (Minneap Minn). 2015;21(4):973-989.
  2. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123-2132.
  3. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51-60.
  4. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine (ADVANCE). N Engl J Med. 2021;385(8):695-706.
  5. Aurora SK, Dodick DW, Turkel CC, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793-803.
  6. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.